InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: NY1972 post# 303

Friday, 08/12/2016 12:45:25 PM

Friday, August 12, 2016 12:45:25 PM

Post# of 977
Notes

As of June 30, 2016, Trillium had cash of $60.1 million.
Net loss for the six months ended June 30, 2016 of $14.8 million

TTI-621, a potent SIRPaFc (IgG1) fusion protein targeting CD47, continues on schedule with a clinical update expected by the end of 2016.

Phase 1 trial with TTI-621 in patients with select solid tumors

Canadian sites to be included in Phase 1b expansion cohorts.